Pfizer (NYSE:PFE) received a $39.00 price target from investment analysts at BMO Capital Markets in a note issued to investors on Tuesday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ target price would suggest a potential upside of 3.17% from the stock’s current price.
Other research analysts have also issued reports about the company. Zacks Investment Research raised Pfizer from a “hold” rating to a “buy” rating and set a $40.00 target price on the stock in a report on Tuesday, October 3rd. Deutsche Bank set a $38.00 target price on Pfizer and gave the stock a “buy” rating in a report on Wednesday, December 6th. Jefferies Group set a $38.00 target price on Pfizer and gave the stock a “neutral” rating in a report on Monday, October 16th. JPMorgan Chase & Co. set a $39.00 target price on Pfizer and gave the stock a “buy” rating in a report on Wednesday, November 1st. Finally, Nord/LB reissued a “neutral” rating on shares of Pfizer in a report on Wednesday, December 27th. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have given a buy rating to the stock. Pfizer currently has an average rating of “Hold” and an average price target of $38.50.
Pfizer (NYSE:PFE) traded down $1.22 during mid-day trading on Tuesday, hitting $37.80. The company had a trading volume of 45,968,924 shares, compared to its average volume of 18,620,000. The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The firm has a market cap of $225,310.00, a price-to-earnings ratio of 23.19, a PEG ratio of 2.41 and a beta of 1.01. Pfizer has a 1-year low of $30.93 and a 1-year high of $39.43.
Pfizer announced that its board has authorized a share repurchase plan on Monday, December 18th that authorizes the company to buyback $10.00 billion in shares. This buyback authorization authorizes the biopharmaceutical company to repurchase shares of its stock through open market purchases. Stock buyback plans are often an indication that the company’s board believes its stock is undervalued.
In other news, insider Alexander R. Mackenzie sold 14,700 shares of the company’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $35.30, for a total transaction of $518,910.00. Following the completion of the sale, the insider now directly owns 117,432 shares in the company, valued at approximately $4,145,349.60. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction on Friday, December 15th. The shares were sold at an average price of $37.07, for a total value of $296,560.00. Following the sale, the executive vice president now owns 46,963 shares of the company’s stock, valued at $1,740,918.41. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 29,450 shares of company stock valued at $1,065,220. Corporate insiders own 0.06% of the company’s stock.
Large investors have recently added to or reduced their stakes in the company. HL Financial Services LLC lifted its position in shares of Pfizer by 1.1% during the 2nd quarter. HL Financial Services LLC now owns 3,222,985 shares of the biopharmaceutical company’s stock worth $108,260,000 after buying an additional 35,744 shares during the last quarter. Hartford Financial Management Inc. lifted its position in shares of Pfizer by 10.8% during the 2nd quarter. Hartford Financial Management Inc. now owns 8,538 shares of the biopharmaceutical company’s stock worth $286,000 after buying an additional 835 shares during the last quarter. Cadence Bank NA lifted its position in shares of Pfizer by 1.4% during the 2nd quarter. Cadence Bank NA now owns 99,962 shares of the biopharmaceutical company’s stock worth $3,358,000 after buying an additional 1,428 shares during the last quarter. Majedie Asset Management Ltd lifted its position in shares of Pfizer by 7.9% during the 2nd quarter. Majedie Asset Management Ltd now owns 336,991 shares of the biopharmaceutical company’s stock worth $11,320,000 after buying an additional 24,531 shares during the last quarter. Finally, Stanley Laman Group Ltd. lifted its position in shares of Pfizer by 373.7% during the 2nd quarter. Stanley Laman Group Ltd. now owns 114,284 shares of the biopharmaceutical company’s stock worth $3,839,000 after buying an additional 90,160 shares during the last quarter. Hedge funds and other institutional investors own 69.87% of the company’s stock.
Pfizer Company Profile
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
